Purple Biotech Sets August 8 Shareholder Meeting
Ticker: PPBT · Form: 6-K · Filed: Jun 26, 2024 · CIK: 1614744
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance
TL;DR
Purple Biotech AGSM on Aug 8. Shareholders vote on company biz.
AI Summary
Purple Biotech Ltd. announced its Annual General Meeting of Shareholders will take place on August 8, 2024, at 4:30 p.m. Israel time. The meeting will be held at the company's offices located at 4 Oppenheimer Street, Science Park, Rehovot, Israel. Shareholders will convene to discuss company matters.
Why It Matters
This meeting is a routine corporate governance event where shareholders can vote on important company decisions and engage with management.
Risk Assessment
Risk Level: low — This filing is a standard notice for an upcoming shareholder meeting, which is a routine corporate event.
Key Players & Entities
- Purple Biotech Ltd. (company) — Registrant
- August 8, 2024 (date) — Annual General Meeting date
- 4:30 p.m. Israel time (time) — Annual General Meeting time
- 4 Oppenheimer Street, Science Park, Rehovot, Israel (location) — Meeting location
FAQ
When is the Purple Biotech Ltd. Annual General Meeting of Shareholders?
The Annual General Meeting of Shareholders of Purple Biotech Ltd. will be held on Thursday, August 8, 2024.
What time will the meeting be held?
The meeting will commence at 4:30 p.m. Israel time.
Where will the Annual General Meeting take place?
The meeting will be held at the company's offices at 4 Oppenheimer Street, Science Park, Rehovot, Israel.
What form does Purple Biotech Ltd. file its annual reports under?
Purple Biotech Ltd. files its annual reports under Form 20-F.
What is the Commission File Number for Purple Biotech Ltd.?
The Commission File Number for Purple Biotech Ltd. is 001-37643.
Filing Stats: 826 words · 3 min read · ~3 pages · Grade level 15.3 · Accepted 2024-06-26 16:30:12
Filing Documents
- ea0208550-6k_purple.htm (6-K) — 17KB
- ea020855001ex99-1_purple.htm (EX-99.1) — 97KB
- ea020855001ex99-2_purple.htm (EX-99.2) — 1KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- ex99-2_001.jpg (GRAPHIC) — 923KB
- ex99-2_002.jpg (GRAPHIC) — 965KB
- 0001213900-24-056189.txt ( ) — 2720KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. June 26, 2024 PURPLE BIOTECH LTD. By: /s/ Lior Fhima Lior Fhima Chief Financial Officer 2